U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24N2O2
Molecular Weight 324.4168
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUININE

SMILES

[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C3=C4C=C(OC)C=CC4=NC=C3

InChI

InChIKey=LOUPRKONTZGTKE-WZBLMQSHSA-N
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1

HIDE SMILES / InChI
Molecular Formula C20H24N2O2
Molecular Weight 324.4168
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM317816.pdf

QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. It’s an alkaloid derived from the bark of the cinchona tree and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented. Quinine inhibits nucleic acid synthesis, protein synthesis, and glycolysis in Plasmodium falciparum and can bind with hemazoin in parasitized erythrocytes. However, the precise mechanism of the antimalarial activity of quinine sulfate is not completely understood. It is thought to act by inhibiting heme polymerase, thereby allowing accumulation of its cytotoxic substrate, heme. As a schizonticidal drug, it is less effective and more toxic than chloroquine. Quinine is FDA-approved. It is not considered safe and effective for the treatment or prevention of leg cramps-- an "off-label" (non-FDA-approved) use. Quinine is associated with serious and life-threatening adverse events, including: thrombocytopenia, hypersensitivity reactions, and QT prolongation. Thrombocytopenia associated with the use of quinine for the treatment or prevention of leg cramps includes: immune thrombocytopenic purpura, hemolytic uremic syndrome, thrombotic thrombocytepenic purpura with associated renal insufficiency.

Approval Year

1921
1447
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2760
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
QUALAQUIN

Approved Use

is a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria

Launch Date

1.12380477E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021799s029lbl.pdf
8.7 mg/kg single, oral
dose: 8.7 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
28 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021799s029lbl.pdf
8.7 mg/kg single, oral
dose: 8.7 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021799s029lbl.pdf
8.7 mg/kg single, oral
dose: 8.7 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
8%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021799s029lbl.pdf
8.7 mg/kg single, oral
dose: 8.7 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 g single, oral
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/2566088
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2566088
Other AEs: Respiratory distress...
Other AEs:
Respiratory distress (grade 5, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2566088
1.8 g single, oral
Overdose
Dose: 1.8 g
Route: oral
Route: single
Dose: 1.8 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/28778932
unhealthy, 46 years
n = 1
Health Status: unhealthy
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/28778932
Other AEs: Hearing loss...
Other AEs:
Hearing loss (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/28778932
16250 mg single, oral
Overdose
Dose: 16250 mg
Route: oral
Route: single
Dose: 16250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8340583
unhealthy, 49 years
n = 1
Health Status: unhealthy
Age Group: 49 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8340583
Other AEs: Cardiotoxicity...
Other AEs:
Cardiotoxicity (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8340583
9.75 g single, oral
Dose: 9.75 g
Route: oral
Route: single
Dose: 9.75 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/14640479
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/14640479
Other AEs: Tachycardia...
Other AEs:
Tachycardia (grade 5)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14640479
AEs

AEs

AESignificanceDosePopulation
Respiratory distress grade 5, 1 patient
5 g single, oral
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/2566088
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2566088
Hearing loss 1 patient
1.8 g single, oral
Overdose
Dose: 1.8 g
Route: oral
Route: single
Dose: 1.8 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/28778932
unhealthy, 46 years
n = 1
Health Status: unhealthy
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/28778932
Cardiotoxicity 1 patient
16250 mg single, oral
Overdose
Dose: 16250 mg
Route: oral
Route: single
Dose: 16250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8340583
unhealthy, 49 years
n = 1
Health Status: unhealthy
Age Group: 49 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8340583
Tachycardia grade 5
9.75 g single, oral
Dose: 9.75 g
Route: oral
Route: single
Dose: 9.75 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/14640479
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/14640479
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:15854
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15854
MolPort
MolPort-000-146-082
https://www.molport.com/shop/molecule-link/MolPort-000-146-082
ZINC
ZINC000003831404
http://zinc15.docking.org/substances/ZINC000003831404
eMolecules
29549573
https://www.emolecules.com/cgi-bin/more?vid=29549573
eMolecules
30151887
https://www.emolecules.com/cgi-bin/more?vid=30151887
eMolecules
6843708
https://www.emolecules.com/cgi-bin/more?vid=6843708
PubMed

PubMed

TitleDatePubMed
The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro.
1999 Jul-Aug
Quinine-induced alterations of electrically evoked otoacoustic emissions and cochlear potentials in guinea pigs.
2001 Apr
Two procedures establishing preference for oral cocaine and lidocaine solutions which do not use an associative history with a reinforcer.
2001 Apr
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons.
2001 Aug
Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum.
2001 Aug
Role of quinine-sensitive ion channels in volume regulation in boar and bull spermatozoa.
2001 Aug
BK channels in human glioma cells.
2001 Feb
Pontine gustatory activity is altered by electrical stimulation in the central nucleus of the amygdala.
2001 Feb
Taste receptor cells that discriminate between bitter stimuli.
2001 Feb 23
Babesiosis.
2001 Jan
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
Effect of extracellular Ca2+ on the quinine-activated current of bullfrog taste receptor cells.
2001 Jan 15
The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake.
2001 Jan-Feb
Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa.
2001 Jul
Covariation in individuals' sensitivities to bitter compounds: evidence supporting multiple receptor/transduction mechanisms.
2001 Jul
Apparent drug failure following artesunate treatment of Plasmodium falciparum malaria in Freetown, Sierra Leone: four case reports.
2001 Jul
Myosin II-dependent cylindrical protrusions induced by quinine in Dictyostelium: antagonizing effects of actin polymerization at the leading edge.
2001 Jun
Lateral parabrachial nucleus lesions in the rat: neophobia and conditioned taste aversion.
2001 Jun
Influence of quinine on catecholamine release evoked by cholinergic stimulation and membrane depolarization from the rat adrenal gland.
2001 Jun
Mechanisms by which intracellular calcium induces susceptibility to secretory phospholipase A2 in human erythrocytes.
2001 Jun 22
Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum.
2001 Mar
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy.
2001 Mar
Capillary electrophoretic separation, immunochemical recognition and analysis of the diastereomers quinine and quinidine and two quinidine metabolites in body fluids.
2001 Mar
Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
2001 Mar 23
The treatment of babesiosis.
2001 Mar 8
Exchange transfusion for severe malaria.
2001 Mar-Apr
Interaction of gustatory and lingual somatosensory perceptions at the cortical level in the human: a functional magnetic resonance imaging study.
2001 May
Chemistry. Synthetic lessons from quinine.
2001 May 24
Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro.
2001 May-Jun
Clinical trial of beta-arteether versus quinine for the treatment of cerebral malaria in children in Yaounde, Cameroon.
2001 May-Jun
Effects of the ion-channel blocker quinine on human sperm volume, kinematics and mucus penetration, and the involvement of potassium channels.
2001 Sep
Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand.
2001 Sep 1
Septic shock due to babesiosis.
2001 Sep 1
HPLC of basic drugs on microparticulate strong cation-exchange materials - a review.
2001 Sep 15
Properties and regulation of organic cation transport in freshly isolated human proximal tubules.
2001 Sep 7
Patents

Patents

JP2002500227A
42
JP2003520193A
19
JP2010042013A
19
JP4679150B2
19
JPH04230322A
19
JPH04357199A
19
JPH067429A
19
JPH1171233A
19
JPS58216146A
19
JPS6112651A
19

Sample Use Guides

In Vivo Use Guide
in adults: 648 mg (two capsules) every 8 hours for 7 days
Route of Administration: Oral
In Vitro Use Guide
Quinine (0-100 uM) stimulates adipogenesis through ERK/S6 (extracellular-signal-regulated kinase/Ribosomal protein S6) signaling, which at least partly functions via taste receptor, type 2, member 106 (T2R106)
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:45:02 UTC 2023
Edited
by admin
on Wed Jul 05 22:45:02 UTC 2023
Record UNII
A7V27PHC7A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUININE
HSDB   INCI   MART.   MI   VANDF   WHO-DD  
INCI  
Official Name English
QUININE [MI]
Common Name English
QUININE [HSDB]
Common Name English
Quinine [WHO-DD]
Common Name English
QUININE [MART.]
Common Name English
REZQUIN
Common Name English
WR297608
Code English
CHININUM PURUM [HPUS]
Common Name English
(8S,9R)-6'-METHOXYCINCHONAN-9-OL
Common Name English
QUININE [VANDF]
Common Name English
QUALAQUIN
Common Name English
NSC-192949
Code English
QUININE [INCI]
Common Name English
CHININUM PURUM
HPUS  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C271
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
WHO-ATC P01BC01
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
CFR 21 CFR 862.3750
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
CFR 21 CFR 310.546
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
DSLD 2588 (Number of products:3)
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
CFR 21 CFR 172.575
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
CFR 21 CFR 310.547
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
NDF-RT N0000175482
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
WHO-VATC QM09AA72
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
WHO-ATC M09AA72
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
LIVERTOX NBK548596
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
Code System Code Type Description
CHEBI
15854
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
CHEBI
137041
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
CHEBI
52251
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
DAILYMED
A7V27PHC7A
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
DRUG CENTRAL
4523
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
FDA UNII
A7V27PHC7A
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
MESH
D011803
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
LACTMED
Quinine
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
IUPHAR
2510
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
ChEMBL
CHEMBL170
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
NSC
192949
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
WIKIPEDIA
QUININE
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
SMS_ID
100000078599
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-003-2
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
HSDB
2501
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
RXCUI
9071
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY RxNorm
CAS
130-95-0
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
NCI_THESAURUS
C794
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
DRUG BANK
DB00468
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
MERCK INDEX
M9447
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY Merck Index
EVMPD
SUB15084MIG
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
PUBCHEM
3034034
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
EPA CompTox
DTXSID0044280
Created by admin on Wed Jul 05 22:45:02 UTC 2023 , Edited by admin on Wed Jul 05 22:45:02 UTC 2023
PRIMARY
Related Record Type Details
Structure of QUININE FORMATE
SALT/SOLVATE -> PARENT
Structure of QUININE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of QUININE ARSENITE
SALT/SOLVATE -> PARENT
Structure of QUININE HYPOPHOSPHITE
SALT/SOLVATE -> PARENT
Structure of QUININE BISULFATE HEPTAHYDRATE
SALT/SOLVATE -> PARENT
OCTN-1
TRANSPORTER -> INHIBITOR
Structure of Penicillin G quinine
SALT/SOLVATE -> PARENT
Structure of Quinine arsenate
SALT/SOLVATE -> PARENT
Structure of QUININE HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
Structure of QUININE HYDROBROMIDE ANHYDROUS
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of QUININE UREA HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of QUININE ASCORBATE
SALT/SOLVATE -> PARENT
Structure of Phenobarbital quinine
SALT/SOLVATE -> PARENT
Structure of QUININE SULFATE
SALT/SOLVATE -> PARENT
OCT-1
TRANSPORTER -> INHIBITOR
Structure of QUININE CITRATE
SALT/SOLVATE -> PARENT
OCT-1
TRANSPORTER -> SUBSTRATE
Structure of QUININE GLUCONATE
SALT/SOLVATE -> PARENT
Structure of QUININE DIHYDROBROMIDE
SALT/SOLVATE -> PARENT
Structure of QUININE SALICYLATE
SALT/SOLVATE -> PARENT
OCT-2
TRANSPORTER -> INHIBITOR
Structure of QUININE DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
OCT-3
TRANSPORTER -> INHIBITOR
Structure of QUININE PHOSPHATE PENTAHYDRATE
SALT/SOLVATE -> PARENT
Structure of QUININE BISULFATE
SALT/SOLVATE -> PARENT
Structure of QUININE PHOSPHATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 2'-OXOQUININE
METABOLITE -> PARENT
PLASMA; URINE
Structure of HYDROQUINIDINE
METABOLITE -> PARENT
URINE
Structure of HYDROXYHYDROQUININE, (10R)-
METABOLITE -> PARENT
MINOR
PLASMA; URINE
Structure of CUPREINE
METABOLITE -> PARENT
URINE
Structure of QUININE GLUCURONIDE
METABOLITE -> PARENT
URINE
Structure of 3-HYDROXYQUININE
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA; URINE
Structure of 3-HYDROXYQUININE
METABOLITE LESS ACTIVE -> PARENT
Quinine is metabolized almost exclusively via hepatic oxidative cytochrome P450 (CYP) pathways. In vitro studies using human liver microsomes and recombinant P450 enzymes have shown that quinine is metabolized mainly by CYP3A4. Depending on the in vitro experimental conditions, other enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were shown to have some role in the metabolism of quinine.
Structure of HYDROXYHYDROQUININE, (10S)-
METABOLITE -> PARENT
MINOR
PLASMA; URINE
Related Record Type Details
Structure of HYDROQUININE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Related Record Type Details
Structure of QUININE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966